Revolution Medicines Inc RVMD:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 06/03/26 EDT155.77
-0.22 (-0.14%)
-0.22 (-0.14%)Volume
37,737
Close
155.99
+4.68 (+3.09%)
+4.68 (+3.09%)Volume
1,954,336
52 week range
34.00 - 166.50
- Open151.57
- Day High156.87
- Day Low151.52
- Prev Close155.99
- 52 Week High166.50
- 52 Week High Date06/01/26
- 52 Week Low34.00
- 52 Week Low Date08/07/25
Latest On Revolution Medicines Inc
Key Stats
- Market Cap33.163B
- Shares Out212.60M
- 10 Day Average Volume3.32M
- Dividend-
- Dividend Yield-
- Beta1.41
Latest On Revolution Medicines Inc
KEY STATS
- Open151.57
- Day High156.87
- Day Low151.52
- Prev Close155.99
- 52 Week High166.50
- 52 Week High Date06/01/26
- 52 Week Low34.00
- 52 Week Low Date08/07/25
- Market Cap33.163B
- Shares Out212.60M
- 10 Day Average Volume3.32M
- Dividend-
- Dividend Yield-
- Beta1.41
RATIOS/PROFITABILITY
- EPS (TTM)-7.09
- P/E (TTM)-21.99
- Fwd P/E (NTM)-21.86
- EBITDA (TTM)-1.378B
- ROE (TTM)-76.67%
- Revenue (TTM)-
- Gross Margin (TTM)-
- Net Margin (TTM)-76,423.31%
- Debt To Equity (MRQ)18.71%
EVENTS
- Earnings Date08/04/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MORERevolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib...
Mark Goldsmith M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Margaret Horn J.D.
Chief Operating Officer
Jack Anders CPA
Chief Financial Officer
Address
700 Saginaw Dr
Redwood City, CA
94063
United States